Arcturus Therapeutics

Arcturus Therapeutics is a preclinical drug delivery and RNA medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.

Placeholder

Arcturus Therapeutics

  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE
  • Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA MedicinesREAD MORE
  • Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation to Advance a Novel LUNAR-Formulated mRNA CFTR TherapeuticREAD MORE
  • Takeda Pharmaceuticals logoTakeda Pharmaceuticals entered into collaboration with Arcturus Therapeutics to develop RNA-based therapeutics for the treatment of NASH.READ MORE
  • Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.READ MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • August 26, 2019

    Arcturus Therapeutics To Present at Two Investor Conferences in September

    • August 26 2019
    • 0
    read more
  • August 15, 2019

    Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update

    • August 15 2019
    • 0
    read more
  • August 7, 2019

    Arcturus to Report Corporate Overview and Financial Results on August 15

    • August 7 2019
    • 0
    read more
  • August 2, 2019

    Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock

    • August 2 2019
    • 0
    read more
  • August 1, 2019

    Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock

    • August 1 2019
    • 0
    read more
  • August 1, 2019

    Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients

    • August 1 2019
    • 0
    read more
  • July 10, 2019

    Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference

    • July 15 2019
    • 0
    read more
  • June 27, 2019

    Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

    • June 27 2019
    • 0
    read more
  • June 19, 2019

    Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

    • June 19 2019
    • 0
    read more